Compare DWSN & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DWSN | CRDF |
|---|---|---|
| Founded | 1952 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 113.3M | 130.7M |
| IPO Year | 1995 | 2012 |
| Metric | DWSN | CRDF |
|---|---|---|
| Price | $2.95 | $1.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $9.63 |
| AVG Volume (30 Days) | 148.3K | ★ 674.1K |
| Earning Date | 03-27-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 71.11 | 27.37 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $145,773,000.00 | $365,993.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 49.61 |
| 52 Week Low | $1.08 | $1.48 |
| 52 Week High | $5.54 | $4.56 |
| Indicator | DWSN | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 40.89 | 45.08 |
| Support Level | $1.56 | $1.51 |
| Resistance Level | $5.54 | $2.05 |
| Average True Range (ATR) | 0.50 | 0.12 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 4.61 | 27.69 |
Dawson Geophysical Co is a provider of onshore seismic data acquisition services with operations throughout the continental United States and Canada. The company acquires and processes 2 D, 3 D, and multi-component seismic data for clients, ranging from oil and gas companies to independent oil and gas operators for use in the onshore drilling and production of oil and natural gas as well as provides multi-client data libraries. It operates through a single segment being Contract seismic data acquisition and processing services. In addition, the company provides multi-component seismic data surveys which involve the recording of alternative seismic waves. Geographically, it generates maximum revenue from the United States.
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.